Cargando…
Patient‐reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment
BACKGROUND: Little is known about long‐term treatment‐related symptoms in older breast cancer survivors. We characterized long‐term patient‐reported symptoms and examined factors associated with the presence and severity of symptoms, and symptom interference with daily activities. METHODS: Texas Can...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524015/ https://www.ncbi.nlm.nih.gov/pubmed/37551136 http://dx.doi.org/10.1002/cam4.6394 |
_version_ | 1785110661163909120 |
---|---|
author | Adesoye, Taiwo Liao, Kai‐Ping Peterson, Susan Li, Liang Zorzi, Daria Holmes, Holly M. Chavez‐MacGregor, Mariana Giordano, Sharon H. |
author_facet | Adesoye, Taiwo Liao, Kai‐Ping Peterson, Susan Li, Liang Zorzi, Daria Holmes, Holly M. Chavez‐MacGregor, Mariana Giordano, Sharon H. |
author_sort | Adesoye, Taiwo |
collection | PubMed |
description | BACKGROUND: Little is known about long‐term treatment‐related symptoms in older breast cancer survivors. We characterized long‐term patient‐reported symptoms and examined factors associated with the presence and severity of symptoms, and symptom interference with daily activities. METHODS: Texas Cancer Registry (TCR) Medicare linkage data was used to identify breast cancer patients age 65 and older with local/regional stage disease diagnosed between 2012–2013. Symptom burden was assessed using breast‐specific items from the Patient‐Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO‐CTCAE™). Demographic and clinical data also were collected. Logistic regression models were used to assess the association between symptom burden and respondent sociodemographic and clinical characteristics. RESULTS: Of 4448 eligible patients, 1594 (response‐rate 35.8%) completed questionnaires. Of these, 1245 eligible respondents were included in the analysis based on self‐reported data. Median time from diagnosis to survey completion was 68 months (IQR: 62–73). Most frequently reported symptoms were fatigue/lack of energy (76.8%), aching muscles (72.1%) and aching joints (72.5%). Receipt of chemotherapy was associated with higher symptom burden. Patients treated with adjuvant chemotherapy had higher risk of numbness/tingling (OR: 3.16; 95% CI: 2.36–4.24), hair loss (OR: 2.72; 95% CI: 2.05–3.60), and fatigue/lack of energy (OR: 1.80; 95% CI: 1.29–2.52). Similarly, patients who received chemotherapy were more likely to report the majority of symptoms as moderate to severe and as interfering with daily activities. CONCLUSION: Receipt of chemotherapy is associated with significant symptom burden more than 5 years after breast cancer treatment. Long‐term chemotherapy impact should be discussed with patients in a shared‐decision making process and approaches to symptom management during survivorship care are needed. |
format | Online Article Text |
id | pubmed-10524015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105240152023-09-28 Patient‐reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment Adesoye, Taiwo Liao, Kai‐Ping Peterson, Susan Li, Liang Zorzi, Daria Holmes, Holly M. Chavez‐MacGregor, Mariana Giordano, Sharon H. Cancer Med RESEARCH ARTICLES BACKGROUND: Little is known about long‐term treatment‐related symptoms in older breast cancer survivors. We characterized long‐term patient‐reported symptoms and examined factors associated with the presence and severity of symptoms, and symptom interference with daily activities. METHODS: Texas Cancer Registry (TCR) Medicare linkage data was used to identify breast cancer patients age 65 and older with local/regional stage disease diagnosed between 2012–2013. Symptom burden was assessed using breast‐specific items from the Patient‐Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO‐CTCAE™). Demographic and clinical data also were collected. Logistic regression models were used to assess the association between symptom burden and respondent sociodemographic and clinical characteristics. RESULTS: Of 4448 eligible patients, 1594 (response‐rate 35.8%) completed questionnaires. Of these, 1245 eligible respondents were included in the analysis based on self‐reported data. Median time from diagnosis to survey completion was 68 months (IQR: 62–73). Most frequently reported symptoms were fatigue/lack of energy (76.8%), aching muscles (72.1%) and aching joints (72.5%). Receipt of chemotherapy was associated with higher symptom burden. Patients treated with adjuvant chemotherapy had higher risk of numbness/tingling (OR: 3.16; 95% CI: 2.36–4.24), hair loss (OR: 2.72; 95% CI: 2.05–3.60), and fatigue/lack of energy (OR: 1.80; 95% CI: 1.29–2.52). Similarly, patients who received chemotherapy were more likely to report the majority of symptoms as moderate to severe and as interfering with daily activities. CONCLUSION: Receipt of chemotherapy is associated with significant symptom burden more than 5 years after breast cancer treatment. Long‐term chemotherapy impact should be discussed with patients in a shared‐decision making process and approaches to symptom management during survivorship care are needed. John Wiley and Sons Inc. 2023-08-08 /pmc/articles/PMC10524015/ /pubmed/37551136 http://dx.doi.org/10.1002/cam4.6394 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Adesoye, Taiwo Liao, Kai‐Ping Peterson, Susan Li, Liang Zorzi, Daria Holmes, Holly M. Chavez‐MacGregor, Mariana Giordano, Sharon H. Patient‐reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment |
title | Patient‐reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment |
title_full | Patient‐reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment |
title_fullStr | Patient‐reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment |
title_full_unstemmed | Patient‐reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment |
title_short | Patient‐reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment |
title_sort | patient‐reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524015/ https://www.ncbi.nlm.nih.gov/pubmed/37551136 http://dx.doi.org/10.1002/cam4.6394 |
work_keys_str_mv | AT adesoyetaiwo patientreportedoutcomesinolderbreastcancersurvivorswithandwithoutpriorchemotherapytreatment AT liaokaiping patientreportedoutcomesinolderbreastcancersurvivorswithandwithoutpriorchemotherapytreatment AT petersonsusan patientreportedoutcomesinolderbreastcancersurvivorswithandwithoutpriorchemotherapytreatment AT liliang patientreportedoutcomesinolderbreastcancersurvivorswithandwithoutpriorchemotherapytreatment AT zorzidaria patientreportedoutcomesinolderbreastcancersurvivorswithandwithoutpriorchemotherapytreatment AT holmeshollym patientreportedoutcomesinolderbreastcancersurvivorswithandwithoutpriorchemotherapytreatment AT chavezmacgregormariana patientreportedoutcomesinolderbreastcancersurvivorswithandwithoutpriorchemotherapytreatment AT giordanosharonh patientreportedoutcomesinolderbreastcancersurvivorswithandwithoutpriorchemotherapytreatment |